Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.96 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.96 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.96 |
| ▸ | PAM | P19021 | 1/20 | 0.66 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | FNTA | P49354 | 1/20 | 0.53 |
| ▸ | FNTB | P49356 | 1/20 | 0.53 |
| ▸ | LIPE | Q05469 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | MGLL | Q99685 | 2/20 | 0.53 |
| ▸ | CASP1 | P29466 | 1/20 | 0.52 |
| ▸ | CES2 | O00748 | 1/20 | 0.52 |
| ▸ | CES1 | P23141 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL361779 | 0.98 | ALDH1A1 (1.00) | ALDH1A1MAPK1L3MBTL1PAMENPP2 | |
| SCHEMBL57331 | 0.94 | ALDH1A1 (0.85) | ALDH1A1MAPK1L3MBTL1PAMENPP2 | |
| SCHEMBL31245908 | 0.94 | ALDH1A1 (0.85) | ALDH1A1MAPK1L3MBTL1PAMENPP2 | |
| SCHEMBL27499661 | 0.94 | ALDH1A1 (0.92) | ALDH1A1MAPK1L3MBTL1PAMENPP2 | |
| SCHEMBL8117331 | 0.93 | ALDH1A1 (0.82) | ALDH1A1MAPK1L3MBTL1PAMENPP2 | |
| SCHEMBL4675591 | 0.91 | ALDH1A1 (0.79) | ALDH1A1MAPK1L3MBTL1PAMENPP2 | |
| SCHEMBL18430348 | 0.91 | ALDH1A1 (0.79) | ALDH1A1MAPK1L3MBTL1PAMENPP2 | |
| SCHEMBL224663 | 0.91 | ALDH1A1 (0.79) | ALDH1A1MAPK1L3MBTL1PAMENPP2 | |
| SCHEMBL22211316 | 0.91 | ALDH1A1 (0.79) | ALDH1A1MAPK1L3MBTL1PAMENPP2 | |
| SCHEMBL9880917 | 0.91 | L3MBTL1 (0.79) | ALDH1A1MAPK1L3MBTL1PAMENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6740760-B2 | SUCH AS 1-((S)-3-MERCAPTO-2-METHYL-PROPIONYL)-(R)-PYRROL-IDINE-2-CARBOXYLIC ACID FOR TREATING DISEASES ASSOCIATED WITH AMYLOIDOSIS (ALZHEIMER'S DISEASE, DIABETES, AND FAMILIAL AMYLOID POLYNEUROPATHY) | HOFFMANN-LA ROCHE INC. | 2004-05-25 | — | — | US | disclosed |
| US-20030100770-A1 | Such as 1-((S)-3-mercapto-2-methyl-propionyl)-(R)-pyrrol-idine-2-carboxylic acid for treating diseases associated with amyloidosis (Alzheimer's disease, diabetes, and familial amyloid polyneuropathy) | PENTRAXIN THERAPEUTICS LTD. (GB) | 2003-05-29 | — | — | US | disclosed |
| US-6512001-B1 | To treat diseases associated with amyloidosis, such as Alzheimer's disease | HOFFMANN-LA ROCHE INC. | 2003-01-28 | — | — | US | disclosed |
| EP-0915088-B1 | D-Proline derivatives | HOFFMANN LA ROCHE (CH) | 2002-09-18 | — | — | EP | disclosed |
| US-6262089-B1 | USING THESE COMPOUNDS TO TREAT DISEASES ASSOCIATED WITH AMYLOIDOSIS, SUCH AS ALZHEIMER'S DISEASE, MATURITY ONSET DIABETES MELLITUS, FAMILIAL AMYLOID POLYNEUROPATHY, SCRAPIE, AND KREUZFELD-JACOB DISEASE. | HOFFMAN-LA ROCHE INC. | 2001-07-17 | — | — | US | disclosed |
| US-6103910-A | FOR TREATMENT OF DISEASES ASSOCIATED WITH AMYLOIDOSIS, SUCH AS ALZHEIMER'S DISEASE, DIABETES MELLITUS, FAMILIAL AMYLOID POLYNEUROPATHY, SCRAPIE, AND KREUZFELD-JACOB DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2000-08-15 | — | — | US | disclosed |
| EP-0915088-A1 | D-Proline derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1999-05-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100770-A1 | Such as 1-((S)-3-mercapto-2-methyl-propionyl)-(R)-pyrrol-idine-2-carboxylic acid for treating diseases associated with amyloidosis (Alzheimer's disease, diabetes, and familial amyloid polyneuropathy) | PSEN1, PSEN2, IAPP | ALDH1A1 175/4885MAPK1 565/4885L3MBTL1 3105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.